Developer docs
API playgroundTry for free, no card

Search company profiles

Lucis Pharma

Full company profile

uuid003i8ty

Namestring
Lucis Pharma
Legal namestring
Lucis Pharma Ltd
Websiteurl
lucispharma.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Lucis Pharma is a privately held UK pharmaceutical company founded in 2012 and headquartered in Blockley, United Kingdom, specializing in the development and licensing of high-quality generic medicines. The company targets the healthcare professional segment — doctors, pharmacists, and other prescribers — alongside end patients seeking affordable medication options, with the stated mission of improving healthcare accessibility and affordability through generic formulations that meet rigorous safety and efficacy standards.

Lucis's core offering is a portfolio of generic medicines marketed through pharmacy and healthcare professional channels, supplemented by pipeline products targeting the unit dose/sachet market segment. The company executed product launches during the 2021/22 period, though specific product names and therapeutic indications are not disclosed in available source material. The underlying business model centers on licensing generic pharmaceutical products, with revenue mechanics structured around one-time licensing arrangements rather than recurring subscription or service fees.

In June 2023, Lucis Pharma was acquired by Rosemont Pharmaceuticals, a larger UK-based specialty pharmaceutical group. Following the acquisition, Lucis operates as a subsidiary within the Rosemont group, with the deal positioned by Rosemont as a vehicle for portfolio broadening, entry into attractive new product areas, and access to Lucis's pipeline including unit dose/sachet formulations. No disclosed financial metrics, headcount, or management team details are available in the source data.

Short descriptiontext

Lucis Pharma is a UK-based private pharmaceutical company founded in 2012 that develops and licenses high-quality generic medicines for healthcare professionals and patients. It was acquired by Rosemont Pharmaceuticals in June 2023.

Operating statusenum
Acquired
Ownership categoryenum
akta.pro rankint
HeadquartersBlockley, United Kingdom
HQ citystring
Blockley
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
generic pharmaceuticals, pharmaceutical licensing, generic drug development, unit dose medicines, pharmaceutical product portfolio
Industry2 codes
PRIMARYHLAIABAL
Generic Hospital & Institutional Products
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Generic Pharmaceutical Products
TypeOne Time License
Description

Revenue generated through development and licensing of high-quality generic medicines. Products are marketed to improve healthcare accessibility and affordability.

rosemontpharma.com
Cost components5 values
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Lucis Pharma develops and licenses high-quality generic medicines focused on improving healthcare accessibility and affordability. The portfolio includes recently launched products from 2021/22 and pipeline products enabling entry into the unit dose/sachet market. Products are marketed to healthcare professionals including doctors, pharmacists, and other prescribers for use in patient care.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Lucis Pharma operates as a specialist pharmaceutical company focused on the development and licensing of high-quality generic medicines. Founded in 2012, the company is committed to improving healthcare accessibility and affordability by delivering effective and safe medications that meet rigorous standards. Following its acquisition by Rosemont Pharmaceuticals in June 2023, Lucis Pharma's portfolio provides access to new product areas and pipeline products, including unit dose/sachet formulations.

Product and service1 record
1Generic Medicines Portfolio
CategoryGeneric Pharmaceuticals
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-01
Description

Rosemont Pharmaceuticals acquired Lucis Pharma Ltd in June 2023. The acquisition brings accelerated growth opportunities through broadened portfolio, access to new attractive product areas, and further pipeline products including unit dose/sachet market entry.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lucis Pharma

Generic Pharmaceuticalslucispharma.com

Lucis Pharma is a UK-based private pharmaceutical company founded in 2012 that develops and licenses high-quality generic medicines for healthcare professionals and patients. It was acquired by Rosemont Pharmaceuticals in June 2023.

What Lucis Pharma does

Lucis Pharma is a privately held UK pharmaceutical company founded in 2012 and headquartered in Blockley, United Kingdom, specializing in the development and licensing of high-quality generic medicines. The company targets the healthcare professional segment — doctors, pharmacists, and other prescribers — alongside end patients seeking affordable medication options, with the stated mission of improving healthcare accessibility and affordability through generic formulations that meet rigorous safety and efficacy standards.

Lucis's core offering is a portfolio of generic medicines marketed through pharmacy and healthcare professional channels, supplemented by pipeline products targeting the unit dose/sachet market segment. The company executed product launches during the 2021/22 period, though specific product names and therapeutic indications are not disclosed in available source material. The underlying business model centers on licensing generic pharmaceutical products, with revenue mechanics structured around one-time licensing arrangements rather than recurring subscription or service fees.

In June 2023, Lucis Pharma was acquired by Rosemont Pharmaceuticals, a larger UK-based specialty pharmaceutical group. Following the acquisition, Lucis operates as a subsidiary within the Rosemont group, with the deal positioned by Rosemont as a vehicle for portfolio broadening, entry into attractive new product areas, and access to Lucis's pipeline including unit dose/sachet formulations. No disclosed financial metrics, headcount, or management team details are available in the source data.

Lucis Pharma firmographics

Firmographics
Name
Lucis Pharma
Legal name
Lucis Pharma Ltd
Website
https://lucispharma.com
Company type
Private
Founded year
2012
Operating status
Acquired
Short description
Lucis Pharma is a UK-based private pharmaceutical company founded in 2012 that develops and licenses high-quality generic medicines for healthcare professionals and patients. It was acquired by Rosemont Pharmaceuticals in June 2023.
Ownership category
akta.pro rank

Lucis Pharma industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAL
Generic Hospital & Institutional Products
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Generic pharmaceuticals
  • Pharmaceutical licensing
  • Generic drug development
  • Unit dose medicines
  • Pharmaceutical product portfolio

Where Lucis Pharma is headquartered

Location

Headquarters

HQ city
Blockley
HQ country
United Kingdom
HQ region
Europe

Markets served

Lucis Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales

Revenue model

  1. Generic Pharmaceutical Products: Revenue generated through development and licensing of high-quality generic medicines. Products are marketed to improve healthcare accessibility and affordability.

Go-to-market motion1 record

Lucis Pharma product offering

Product offering

Core offering

Lucis Pharma develops and licenses high-quality generic medicines focused on improving healthcare accessibility and affordability. The portfolio includes recently launched products from 2021/22 and pipeline products enabling entry into the unit dose/sachet market. Products are marketed to healthcare professionals including doctors, pharmacists, and other prescribers for use in patient care.

Product overview

Lucis Pharma operates as a specialist pharmaceutical company focused on the development and licensing of high-quality generic medicines. Founded in 2012, the company is committed to improving healthcare accessibility and affordability by delivering effective and safe medications that meet rigorous standards. Following its acquisition by Rosemont Pharmaceuticals in June 2023, Lucis Pharma's portfolio provides access to new product areas and pipeline products, including unit dose/sachet formulations.

Differentiator

Problem solved

Functional benefit

Products and services

  • Generic Medicines Portfolio

Companies that use Lucis Pharma

Customer profile

Segments2 records

Ideal customer profiles1 record

Lucis Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Lucis Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Rosemont PharmaceuticalscoreStrategic or Co-development Partner · 1 June 2023Rosemont Pharmaceuticals acquired Lucis Pharma Ltd in June 2023. The acquisition brings accelerated growth opportunities through broadened portfolio, access to new attractive product areas, and further pipeline products including unit dose/sachet market entry.

Scale indicators1 record

Recent moves3 records

Expansion highlights2 records

Lucis Pharma competitors and assessment

Company assessment

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks4 records

Customer concentration

Lucis Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lucis Pharma leadership team

Management profile

Number of profiles

Lucis Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lucis Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lucis Pharma

What does Lucis Pharma do?

Lucis Pharma develops and licenses high-quality generic medicines focused on improving healthcare accessibility and affordability. The portfolio includes recently launched products from 2021/22 and pipeline products enabling entry into the unit dose/sachet market. Products are marketed to healthcare professionals including doctors, pharmacists, and other prescribers for use in patient care.

Is Lucis Pharma a public or private company?

Lucis Pharma is a private company. It is classified as corporate owned and is currently acquired.

When was Lucis Pharma founded?

Lucis Pharma was founded in 2012.

Where is Lucis Pharma based?

Lucis Pharma is headquartered in Blockley, United Kingdom, in the Europe region.

How does Lucis Pharma make money?

One revenue line is on record: generic Pharmaceutical Products.

Does Lucis Pharma have an API?

No public API is recorded for Lucis Pharma.

What industry is Lucis Pharma in?

Lucis Pharma's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
RosemontpharmaRosemont expands its offering with portfolio acquisition from Lucis Pharma LtdRosemont Pharmaceuticals has acquired Lucis Pharma Ltd, a UK-based specialist pharmaceutical business, to expand its product portfolio and access new pipeline products. This acquisition allows Rosemont to enter the unit dose and sachet market while leveraging Lucis's existing product launches and developer relationships.PharmiWeb.comRosemont expands its offering with portfolio acquisition from Lucis Pharma LtdRosemont Pharmaceuticals announced the acquisition of Lucis Pharma Ltd, a UK-based specialist pharmaceutical business, to expand its product portfolio and access new pipeline products. The deal provides Rosemont with entry into the unit dose and sachet market, leveraging Lucis's existing SKUs and development capabilities for dysphagic patients. This strategic move aims to accelerate growth in both domestic and international markets.European Pharmaceutical ManufacturerRosemont expands its offering with portfolio acquisition from Lucis Pharma LtdRosemont Pharmaceuticals has acquired Lucis Pharma Ltd, a UK-based specialist pharmaceutical business, to expand its product portfolio and access new pipeline innovations. This transaction allows Rosemont to enter the unit dose/sachet market and accelerate growth through recent Lucis product launches.PharmaTimesRosemont acquires Lucis Pharma to boost portfolioRosemont Pharmaceuticals has acquired Lucis Pharma, a UK-based specialist pharmaceutical business, to expand its portfolio of liquid medicines. The deal grants Rosemont access to Lucis's pipeline of novel treatments and entry into the unit dose or sachet markets, with significant product launches expected during 2021/22.